Curaxys is about to enter the European and international market offering an important updated portfolio of generics and biologic products.


A brief introduction

As soon as patents expire, biopharmaceuticals can be produced and marketed by manufacturers other than the originator. These new biotechnology medicines are known as “biosimilars” or “similar biological medicinal products” because they are claimed to be highly similar to an already approved reference product.

According to the European regulatory framework, biosimilarity means that the a biological product is highly similar to the licensed reference biological product, notwithstanding minor differences in clinically inactive components; and that there are no clinically meaningful differences between the biologic product and the reference product in terms of the safety, purity, and potency of the product.

In 2006, the first biosimilars have received European regulatory approval, therefore becoming a commercial reality in European markets.

CRX02 (Trastuzumab)

Breast cancer is the most common cancer among women worldwide. Each year, 1.4 million new cases are diagnosed around the world, and over 450,000 people will die from the disease annually. One out of four affected women develops the so-called “HER2-positive” breast cancer, a very aggressive type of tumor that responds very poorly to chemotherapy.

Trastuzumab is a humanised monoclonal antibody, specifically designed to activate the body´s immune system and suppress the HER2 protein, to target and destroy the tumour. This increases the overall survival of patients, even in late-stage breast cancer.
The technological platform developed by Curaxys allows the production of clinical-grade Trastuzumab with the highest rates available so far, at a very competitive price.

More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.

Latest News

  • Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012
  • Curaxys hires five more technologists.
  • One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.
  • Innovaxis, a novel company for “custom medicine”
  • Strategic Alliance for cancer disease
  • UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins
  • Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

  • Copyright 2012 Curaxys. All Rights Reserved
    Legal Advice